Author: Erin Zinn

Sustained Treatment Response and Global Improvements With Long-term Valbenazine in Patients Purpose/Background: Using data from KINECT® 4, a phase 3, 48-week study of valbenazine, post…

An Evidence‐Based Update on Anticholinergic Use for Drug‐InducedMovement Disorders Drug-induced movement disorders (DIMDs) are associated with use of dopamine receptor blocking agents (DRBAs), including antipsychotics.…

VMAT2 Inhibitors for the Treatment of Tardive Dyskinesia Psychiatric nurses are at the forefront of optimizing psychiatric care, including educating patientsand caregivers on the risks…